Oruka Therapeutics (ORKA) to Release Earnings on Thursday

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect Oruka Therapeutics to post earnings of ($0.68) per share for the quarter.

Oruka Therapeutics Price Performance

ORKA stock opened at $10.64 on Wednesday. The stock has a market capitalization of $372.39 million, a P/E ratio of -1.70 and a beta of 0.77. Oruka Therapeutics has a one year low of $10.52 and a one year high of $53.88. The business’s 50 day simple moving average is $15.17.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $45.00 price target on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $39.86.

Get Our Latest Stock Analysis on ORKA

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

See Also

Earnings History for Oruka Therapeutics (NASDAQ:ORKA)

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.